… represent the most common pathogens aggravating oral mucositis in the course of antineoplastic
therapy. For seropositive and myelosuppressed patients, topical and systemic acyclovir …

… Articles that evaluated amifostine for the prevention and/or treatment of cancer therapy-induced
oral mucositis in humans were selected for review. The detailed inclusion and exclusion …

… and cancer therapy continuity. It is a challenge for radiation oncologists since it leads to cancer
therapy … RIOM occurs in 100% of altered fractionation radiotherapy head and neck cancer …

… Oral mucositis can become one of the most distressing and uncomfortable side effects of
cancer therapy… , such as potential interruptions in cancer treatment, dosage reductions, reduced …

… Oral mucositis (OM) is the main complication resulting from antineoplastic treatment. Oral
manifestations occur approximately 5 to 14 days after drug administration, with infections and …

… oral dysfunction in relation to oral mucositis and examined the extent to which oral dysfunction
and distress correlated with oral mucositis… Oral mucositis is the most symptomatic problem …

… positive evidence to support a suggestion in favor of using oral care protocols for the
prevention of oral mucositis across all cancer treatment modalities (Table 4). The evidence also …

… Oral mucositis is defined as inflammation of oral mucosa resulting from cancer therapy
typically manifesting as atrophy, swelling, erythema and ulceration. The condition may be …

… oral mucositis to a prominent toxicity of cancer therapy. A contemporary model for mucositis
… strategies in the future, with positive impact on quality of life and survival of cancer patients. …

… At the end of the study, despite this being 3 weeks after completion of cancer therapy, all
OM, pain, and oral functional scores remained elevated than baseline, reflecting severe oral …